Cardiovascular disease and the renal transplant recipient

American Journal of Kidney Diseases

Volumn 38, Issue 6 SUPPL. 6, 2001, Pages

  Kendrick, Elizabeth ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease (CVD); Homocysteine; Hyperlipidemia; Hypertension; Kidney transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; VERAPAMIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MORBIDITY; MORTALITY; NEPHROTOXICITY; PERIPHERAL VASCULAR DISEASE;

EID: 0035720924     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.28924     Document Type: Article

References (90)

1. Left ventricular hypertrophy in the renal patient
2. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
3. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
4. Evidence that triglycerides are an independent coronary heart disease risk factor
5. Coronary heart disease in chronic renal insufficiency: Some management considerations
6. Homocysteine and cardiovascular disease
7. Homocysteine and renal disease
8. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction
9. Long-term survival in renal transplant recipients with graft function
10. Explained and unexplained ischemic heart disease risk after renal transplantation
11. Renal function and blood pressure in patients receiving long-term low-dose cyclosporine therapy for idiopathic uveitis
12. Hypertension in the kidney transplant patient
13. Hypertension after renal transplantation
14. Pathophysiology and treatment of posttransplant hypertension
15. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study
16. Cardiovascular disease after renal transplantation
17. Hypertension and allograft nephropathy - Cause, consequence, or both?
18. Association of chronic kidney graft failure with recipient blood pressure. Collaborative transplant study
19. Management of patients with hypertension and diabetes mellitus: Advances in the evidence for intensive treatment
20. Preserving renal function in adults with hypertension and diabetes: A consensus approach
21. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients
22. Safety of nifedipine in angina pectoris: A meta-analysis
23. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
24. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
25. Cardiac protection: Evolving role of angiotensin receptor blockers
26. Comparison of quinapril versus atenolol: Effects on blood pressure and cardiac mass after renal transplantation
27. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism
28. Influence of angiotensin-converting enzyme inhibitor treatment of the carotid artery intima-media complex in renal allograft recipients
29. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients
30. Can ACE inhibitors prevent chronic allograft failure?
31. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy
32. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients
33. Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension
34. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI)
35. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study
36. Long-term posttransplantation management and complications
37. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection
38. Hyperlipidaemia in renal transplant patients
39. Dyslipidaemia and the progression of renal disease in chronic renal failure patients
40. The role of lipids in renal disease: Future challenges
41. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial
42. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine
43. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
44. Optimal resources for primary prevention of atherosclerotic diseases
45. Cholesterol and coronary heart disease. A new era
46. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
47. The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation
48. Patient profile and effect of dietary therapy on post-transplant hyperlipidemia
49. Rapid improvement of hyperlipidemia in kidney transplant patients with a multifactorial hypolipidemic diet
50. Effects of Mediterranean diet on lipid levels and cardiovascular risk in renal transplant recipients
51. Therapy of post-renal transplantation hyperlipidaemia: Comparative study with simvastatin and fish oil
52. Effects of nicotinic acid and lovastatin in renal transplant patients: A prospective, randomized, open-labeled cross-over trial
53. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients
54. Lovastatin treatment of hypercholesterolemia in renal transplant recipients
55. The effects of pravastatin on hyperlipidemia in renal transplant recipients
56. Low dose simvastatin is safe in hyperlipidemic transplant patients treated with cyclosporine
57. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients
58. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins
59. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism-monograph for physicians
60. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
61. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine
62. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients
63. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience
64. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
65. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients
66. Management of hyperlipidemia in the stable solid organ transplant recipient
67. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients
68. Oxidizability of low-density lipoproteins from neoral and tacrolimus-treated renal transplant patients
69. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients
70. Immunosuppression enhances atherogenicity of lipid profile after transplantation
71. Homocysteine and coronary heart disease: A review of the current evidence
72. Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients
73. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
74. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients
75. Homocysteinemia and vascular disease in end-stage renal disease
76. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
77. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients
78. Serum total homocysteine concentration does not predict outcome in renal transplant recipients
79. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol
80. Conversion to tacrolimus in hyperlipidemic patients
81. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study
82. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus
83. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal study group
84. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
85. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study
86. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients
87. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children posttransplantation in the cyclosporine era
88. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis
89. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy